290 related articles for article (PubMed ID: 19887601)
21. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).
Kim R; Tanabe K; Uchida Y; Osaki A; Toge T
Oncol Rep; 2002; 9(1):3-9. PubMed ID: 11748447
[TBL] [Abstract][Full Text] [Related]
22. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
23. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
24. A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines.
Kim EM; Lobocki C; Dubay L; Mittal VK
Am J Surg; 2009 Mar; 197(3):331-6. PubMed ID: 19245910
[TBL] [Abstract][Full Text] [Related]
25. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.
Zhang KX; Kim C; Chow E; Chen IS; Jia W; Rennie PS
Breast Cancer Res Treat; 2011 Jan; 125(1):89-97. PubMed ID: 20232140
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
27. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
Ali SM; Carney WP; Esteva FJ; Fornier M; Harris L; Köstler WJ; Lotz JP; Luftner D; Pichon MF; Lipton A;
Cancer; 2008 Sep; 113(6):1294-301. PubMed ID: 18661530
[TBL] [Abstract][Full Text] [Related]
28. Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.
Voutsas IF; Mahaira LG; Fotopoulou K; Kapranos N; Reclos JG; Gritzapis AD; Papamichail M; Perez SA; Baxevanis CN
Int J Radiat Biol; 2013 May; 89(5):319-25. PubMed ID: 23311575
[TBL] [Abstract][Full Text] [Related]
29. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
30. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.
Biroccio A; D'Angelo C; Jansen B; Gleave ME; Zupi G
J Cell Physiol; 2005 Aug; 204(2):463-9. PubMed ID: 15685647
[TBL] [Abstract][Full Text] [Related]
31. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
32. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.
Narayan M; Wilken JA; Harris LN; Baron AT; Kimbler KD; Maihle NJ
Cancer Res; 2009 Mar; 69(6):2191-4. PubMed ID: 19276389
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
[TBL] [Abstract][Full Text] [Related]
36. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
37. Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.
Berghoff AS; Bago-Horvath Z; Dubsky P; Rudas M; Pluschnig U; Wiltschke C; Gnant M; Steger GG; Zielinski CC; Bartsch R
Breast J; 2013; 19(2):149-55. PubMed ID: 23350584
[TBL] [Abstract][Full Text] [Related]
38. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.
Ramić S; Asić K; Balja MP; Paić F; Benković V; Knežević F
Anticancer Res; 2013 Jun; 33(6):2509-15. PubMed ID: 23749902
[TBL] [Abstract][Full Text] [Related]
39. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors.
Zindy P; Bergé Y; Allal B; Filleron T; Pierredon S; Cammas A; Beck S; Mhamdi L; Fan L; Favre G; Delord JP; Roché H; Dalenc F; Lacroix-Triki M; Vagner S
Cancer Res; 2011 Jun; 71(12):4068-73. PubMed ID: 21498638
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between overexpression of HER-2/neu protein and prognosis in epithelial ovarian cancer].
Sasaki N; Takano M; Kudou K; Kita T; Kikuchi Y
Nihon Rinsho; 2004 Oct; 62 Suppl 10():582-6. PubMed ID: 15535312
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
